JP2022543021A5 - - Google Patents

Info

Publication number
JP2022543021A5
JP2022543021A5 JP2022506342A JP2022506342A JP2022543021A5 JP 2022543021 A5 JP2022543021 A5 JP 2022543021A5 JP 2022506342 A JP2022506342 A JP 2022506342A JP 2022506342 A JP2022506342 A JP 2022506342A JP 2022543021 A5 JP2022543021 A5 JP 2022543021A5
Authority
JP
Japan
Prior art keywords
cancer
tak
administration
treatment
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543021A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/070080 external-priority patent/WO2020243745A1/en
Publication of JP2022543021A publication Critical patent/JP2022543021A/ja
Publication of JP2022543021A5 publication Critical patent/JP2022543021A5/ja
Priority to JP2025093180A priority Critical patent/JP2025143272A/ja
Pending legal-status Critical Current

Links

JP2022506342A 2019-05-29 2020-05-28 がんを処置する方法及び使用 Pending JP2022543021A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025093180A JP2025143272A (ja) 2019-05-29 2025-06-04 がんを処置する方法及び使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962853842P 2019-05-29 2019-05-29
US62/853,842 2019-05-29
PCT/US2020/070080 WO2020243745A1 (en) 2019-05-29 2020-05-28 Methods and uses for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025093180A Division JP2025143272A (ja) 2019-05-29 2025-06-04 がんを処置する方法及び使用

Publications (2)

Publication Number Publication Date
JP2022543021A JP2022543021A (ja) 2022-10-07
JP2022543021A5 true JP2022543021A5 (cg-RX-API-DMAC7.html) 2023-06-06

Family

ID=73553943

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506342A Pending JP2022543021A (ja) 2019-05-29 2020-05-28 がんを処置する方法及び使用
JP2025093180A Pending JP2025143272A (ja) 2019-05-29 2025-06-04 がんを処置する方法及び使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025093180A Pending JP2025143272A (ja) 2019-05-29 2025-06-04 がんを処置する方法及び使用

Country Status (11)

Country Link
US (1) US11911374B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976036A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022543021A (cg-RX-API-DMAC7.html)
KR (1) KR20220002745A (cg-RX-API-DMAC7.html)
CN (2) CN119326899A (cg-RX-API-DMAC7.html)
AU (1) AU2020283913A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021026294A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141072A1 (cg-RX-API-DMAC7.html)
IL (1) IL288591B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021014686A (cg-RX-API-DMAC7.html)
WO (1) WO2020243745A1 (cg-RX-API-DMAC7.html)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170326118A1 (en) * 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
CN102015705B (zh) * 2008-02-26 2013-11-13 武田药品工业株式会社 稠合的杂环衍生物及其用途
BR112012004149A2 (pt) * 2009-08-25 2016-03-22 Abraxis Bioscience Llc terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog
CA2801891C (en) 2010-06-07 2020-10-27 Abraxis Bioscience, Llc Combination therapy methods for treating proliferative diseases
JP2012097032A (ja) * 2010-11-02 2012-05-24 Takeda Chem Ind Ltd 併用医薬
WO2014165644A2 (en) * 2013-04-04 2014-10-09 The General Hospital Corporation Combination treatments with sonic hedgehog inhibitors
US9814703B2 (en) * 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
US10329304B2 (en) * 2014-09-12 2019-06-25 Vanderbilt University Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase
WO2016141084A1 (en) * 2015-03-03 2016-09-09 The Board Of Trustees Of The Leland Stanford Junior University Producing mesodermal cell types and methods of using the same
WO2017100533A1 (en) * 2015-12-09 2017-06-15 Board Of Regents, The University Of Texas System Polymeric drug delivery systems for treatment of disease
CN108853507A (zh) * 2017-05-11 2018-11-23 复旦大学 一种抗肿瘤的增效药物组合物及其制备方法和用途
WO2019100003A1 (en) * 2017-11-17 2019-05-23 Yoon Jaeyoung Combination therapy targeting cancer associated with the hedgehog pathway

Similar Documents

Publication Publication Date Title
JP7332293B2 (ja) バルリチニブおよび抗癌剤を含んでなる併用療法
Higuchi et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2)
JP2010514787A5 (cg-RX-API-DMAC7.html)
JP2019530752A (ja) がんを治療するための薬物の調製における、抗pd‐1抗体とvegfr阻害剤とを組み合わせた使用
JP2016536352A5 (cg-RX-API-DMAC7.html)
JP2021522193A5 (cg-RX-API-DMAC7.html)
FI3463345T3 (fi) Farmaseuttisia yhdistelmiä
JP2016515586A5 (cg-RX-API-DMAC7.html)
JP2019506392A5 (cg-RX-API-DMAC7.html)
JP2019038796A5 (cg-RX-API-DMAC7.html)
JP2024524461A5 (cg-RX-API-DMAC7.html)
EP2164573A1 (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
WO2017184086A1 (en) Method of treating liver cancer
Font et al. Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer
JP2021511344A5 (cg-RX-API-DMAC7.html)
Afranie-Sakyi et al. The toxicity of anti-VEGF agents when coupled with standard chemotherapeutics
Tanaka et al. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience
Hahn et al. Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer
JP2006528696A (ja) 抗癌剤の抗腫瘍活性を増強する方法
JP2023517671A5 (cg-RX-API-DMAC7.html)
JP2023522325A5 (cg-RX-API-DMAC7.html)
Fujitani et al. Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer
Walsh et al. Multimodal therapy versus surgery alone for squamous cell carcinoma of the esophagus: a prospective randomized trial
Cho et al. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer
RU2021138875A (ru) Способы и применения для лечения рака